A Triterpene Glycoside from Black Cohosh that Inhibits Osteoclastogenesis by Modulating RANKL and TNFα Signaling Pathways

Chemistry and Biology

Volumn 14, Issue 7, 2007, Pages 860-869

  Qiu, Samuel X ^a   Dan, Chun ^b   Ding, Li Sheng ^b   Peng, Shulin ^b   Chen, Shao Nong ^c   Farnsworth, Norman R ^c   Nolta, Jan ^d   Gross, Michael L ^a   Zhou, Ping ^d  

^a WASHINGTON UNIVERSITY   (United States)

^b CHENGDU INSTITUTE OF BIOLOGY   (China)

^c Chicago College of Pharmacy   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CHEMBIOL; SIGNALING

Indexed keywords

25 O ACETYLCIMIGENOL 3 O BETA D XYLOPYRANOSIDE; 25-O-ACETYLCIMIGENOL-3-O-BETA-D-XYLOPYRANOSIDE; GLYCOSIDE; OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, MOUSE; TRITERPENE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; C57BL MOUSE; CELL DIVISION; CHEMISTRY; CIMICIFUGA; CYTOLOGY; DRUG EFFECT; METABOLISM; MOUSE; OSTEOCLAST; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIVISION; CIMICIFUGA; GLYCOSIDES; MICE; MICE, INBRED C57BL; OSTEOCLASTS; RANK LIGAND; SIGNAL TRANSDUCTION; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

CIMICIFUGA DAHURICA; CIMICIFUGA RACEMOSA;

EID: 34447566882     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2007.06.010     Document Type: Article

References (58)

1. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
2. Teitelbaum S.L., and Ross F.P. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4 (2003) 638-649
3. Weitzmann M.N., and Pacifici R. Estrogen regulation of immune cell bone interactions. Ann. N Y Acad. Sci. 1068 (2006) 256-274
4. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., Han K., DiGregorio G.B., Katzenellenbogen J.A., Katzenellenbogen B.S., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104 (2001) 719-730
5. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., and Cummings S.R. Estrogen replacement therapy and fractures in older women. Study of osteoporotic fractures research group. Ann. Intern. Med. 122 (1995) 9-16
6. Cetinkaya Mehmet B., Kokcu A., Yanik Filiz F., Basoglu T., Malatyalioglu E., and Alper T. Comparison of the effects of transdermal estrogen, oral estrogen, and oral estrogen-progestogen therapy on bone mineral density in postmenopausal women. J. Bone Miner. Metab. 20 (2002) 44-48
7. Colditz G.A. Hormone replacement therapy increases the risk of breast cancer. Ann. N Y Acad. Sci. 833 (1997) 129-136
8. Rossouw Jacques E., Anderson Garnet L., Prentice Ross L., LaCroix Andrea Z., Kooperberg C., Stefanick Marcia L., Jackson Rebecca D., Beresford Shirley A.A., Howard Barbara V., Johnson Karen C., Kotchen Jane M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288 (2002) 321-333
9. Conte P., and Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9 Suppl 4 (2004) 28-37
10. Cappuzzo K.A., and Delafuente J.C. Teriparatide for severe osteoporosis. Ann. Pharmacother. 38 (2004) 294-302
11. Chen S.-N., Fabricant D.S., Lu Z.-Z., Fong H.H.S., and Farnsworth N.R. Cimiracemosides I-P, new 9,19-cyclolanostane triterpene glycosides from Cimicifuga racemosa. J. Nat. Prod. 65 (2002) 1391-1397
12. Wuttke W., Seidlova-Wuttke D., and Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 44 Suppl 1 (2003) S67-S77
13. Liske E., Hanggi W., Henneicke-von Zepelin H.H., Boblitz N., Wustenberg P., and Rahlfs V.W. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J. Womens Health Gend. Based Med. 11 (2002) 163-174
14. Osmers R., Friede M., Liske E., Schnitker J., Freudenstein J., and Henneicke-von Zepelin H.-H. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet. Gynecol. 105 (2005) 1074-1083
15. Nisslein T., and Freudenstein J. Effects of an isopropanolic extract of Cimicifuga racemosa on urinary crosslinks and other parameters of bone quality in an ovariectomized rat model of osteoporosis. J. Bone Miner. Metab. 21 (2003) 370-376
16. Seidlova-Wuttke D., Jarry H., Becker T., Christoffel V., and Wuttke W. Pharmacology of Cimicifuga racemosa extract BNO 1055 in rats: bone, fat and uterus. Maturitas 44 Suppl 1 (2003) S39-S50
17. Zierau O., Bodinet C., Kolba S., Wulf M., and Vollmer G. Antiestrogenic activities of Cimicifuga racemosa extracts. J. Steroid Biochem. Mol. Biol. 80 (2002) 125-130
18. Kretzschmar G., Nisslein T., Zierau O., and Vollmer G. No estrogen-like effects of an isopropanolic extract of Rhizoma Cimicifugae racemosae on uterus and vena cava of rats after 17 day treatment. J. Steroid Biochem. Mol. Biol. 97 (2005) 271-277
19. Dixon-Shanies D., and Shaikh N. Growth inhibition of human breast cancer cells by herbs and phytoestrogens. Oncol. Rep. 6 (1999) 1383-1387
20. Burdette J.E., Liu J., Chen S.-n., Fabricant D.S., Piersen C.E., Barker E.L., Pezzuto J.M., Mesecar A., Van Breemen R.B., Farnsworth N.R., and Bolton J.L. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J. Agric. Food Chem. 51 (2003) 5661-5670
21. Freudenstein J., Dasenbrock C., and Bisslein T. Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract. Cancer Res. 62 (2002) 3448-3452
22. Shao Y., Harris A., Wang M., Zhang H., Cordell G.A., Bowman M., and Lemmo E. Triterpene glycosides from Cimicifuga racemosa. J. Nat. Prod. 63 (2000) 905-910
23. Chen S.-N., Li W., Fabricant D.S., Santarsiero B.D., Mesecar A., Fitzloff J.F., Fong H.H.S., and Farnsworth N.R. Isolation, structure elucidation, and absolute configuration of 26-deoxyactein from Cimicifuga racemosa and clarification of nomenclature associated with 27-deoxyactein. J. Nat. Prod. 65 (2002) 601-605
24. Chen S.-N., Fabricant D.S., Lu Z.-Z., Zhang H., Fong H.H.S., and Farnsworth N.R. Cimiracemates A-D, phenylpropanoid esters from the rhizomes of Cimicifuga racemosa. Phytochemistry 61 (2002) 409-413
25. Watanabe K., Mimaki Y., Sakagami H., and Sashida Y. Cycloartane glycosides from the rhizomes of Cimicifuga racemosa and their cytotoxic activities. Chem. Pharm. Bull. (Tokyo) 50 (2002) 121-125
26. Omobuwajo O.R., Martin M.T., Perromat G., Sevenet T., Awang K., and Pais M. Cytotoxic cycloartanes from Aglaia argentea. Phytochemistry 41 (1996) 1325-1328
27. Mohamad K., Martin M.T., Leroy E., Tempete C., Sevenet T., Awang K., and Paies M. Argenteanones C-E and argenteanols B-E, cytotoxic cycloartanes from Aglaia argentea. J. Nat. Prod. 60 (1997) 81-85
28. Tian Z., Yang M., Huang F., Li K., Si J., Shi L., Chen S., and Xiao P. Cytotoxicity of three cycloartane triterpenoids from Cimicifuga dahurica. Cancer Lett. 226 (2005) 65-75
29. Tian Z., Pan R.L., Si J.Y., and Xiao P.G. Cytotoxicity of cycloartane triterpenoids from aerial part of Cimicifuga foetida. Fitoterapia 77 (2006) 39-42
30. Burdette J.E., Chen S.-n., Lu Z.-Z., Xu H., White B.E.P., Fabricant D.S., Liu J., Fong H.H.S., Farnsworth N.R., Constantinou A.I., et al. Black cohosh (Cimicifuga racemosa L.) protects against menadione-induced DNA damage through scavenging of reactive oxygen species: bioassay-directed isolation and characterization of active principles. J. Agric. Food Chem. 50 (2002) 7022-7028
31. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., and Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111 (2003) 1221-1230
32. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., and Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 98 (2001) 13960-13965
33. Pixley F.J., and Stanley E.R. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 14 (2004) 628-638
34. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., Steiner G., Smolen J.S., Wagner E.F., and Schett G. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110 (2002) 1419-1427
35. Ritchlin C.T., Haas-Smith S.A., Li P., Hicks D.G., and Schwarz E.M. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 111 (2003) 821-831
36. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., and Teitelbaum S.L. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106 (2000) 1481-1488
37. Cenci S., Weitzmann M.N., Gentile M.A., Aisa M.C., and Pacifici R. M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. J. Clin. Invest. 105 (2000) 1279-1287
38. Zheng H., Yu X., Collin-Osdoby P., and Osdoby P. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-β via NF-κB that restrains osteoclastogenesis and bone resorption. J. Biol. Chem. 281 (2006) 15809-15820
39. Matsumoto M., Sudo T., Maruyama M., Osada H., and Tsujimoto M. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett. 486 (2000) 23-28
40. Ikeda F., Nishimura R., Matsubara T., Tanaka S., Inoue J., Reddy S.V., Hata K., Yamashita K., Hiraga T., Watanabe T., et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114 (2004) 475-484
41. Ishida N., Hayashi K., Hoshijima M., Ogawa T., Koga S., Miyatake Y., Kumegawa M., Kimura T., and Takeya T. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem. 277 (2002) 41147-41156
42. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., and Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3 (1997) 1285-1289
43. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., Leonardi A., Tran T., Boyce B.F., and Siebenlist U. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11 (1997) 3482-3496
44. Ruocco M.G., Maeda S., Park J.M., Lawrence T., Hsu L.C., Cao Y., Schett G., Wagner E.F., and Karin M. I{κ}B kinase (IKK){β}, but not IKK{α}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201 (2005) 1677-1687
45. Jimi E., Aoki K., Saito H., D'Acquisto F., May M.J., Nakamura I., Sudo T., Kojima T., Okamoto F., Fukushima H., et al. Selective inhibition of NF-κ B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10 (2004) 617-624
46. Dai S., Hirayama T., Abbas S., and Abu-Am Y. The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem. 279 (2004) 37219-37222
47. Chang F., Steelman L.S., Lee J.T., Shelton J.G., Navolanic P.M., Blalock W.L., Franklin R.A., and McCubrey J.A. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17 (2003) 1263-1293
48. De Smaele E., Zazzeroni F., Papa S., Nguyen D.U., Jin R., Jones J., Cong R., and Franzoso G. Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling. Nature 414 (2001) 308-313
49. Tang G., Minemoto Y., Dibling B., Purcell N.H., Li Z., Karin M., and Lin A. Inhibition of JNK activation through NF-κB target genes. Nature 414 (2001) 313-317
50. Kamata H., Honda S., Maeda S., Chang L., Hirata H., and Karin M. Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120 (2005) 649-661
51. Romas E., Gillespie M.T., and Martin T.J. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 30 (2002) 340-346
52. Kitaura H., Sands M.S., Aya K., Zhou P., Hirayama T., Uthgenannt B., Wei S., Takeshita S., Novack D.V., Silva M.J., et al. Marrow stromal cells and osteoclast precursors differentially contribute to TNF-α-induced osteoclastogenesis in vivo. J. Immunol. 173 (2004) 4838-4846
53. Kitaura H., Zhou P., Kim H.J., Novack D.V., Ross F.P., and Teitelbaum S.L. M-CSF mediates TNF-induced inflammatory osteolysis. J. Clin. Invest. 115 (2005) 3418-3427
54. Wei S., Kitaura H., Zhou P., Ross F.P., and Teitelbaum S.L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115 (2005) 282-290
55. Viereck V., Grundker C., Friess S.C., Frosch K.H., Raddatz D., Schoppet M., Nisslein T., Emons G., and Hofbauer L.C. Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. J. Bone Miner. Res. 20 (2005) 2036-2043
56. Lam J., Nelson C.A., Ross F.P., Teitelbaum S.L., and Fremont D.H. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J. Clin. Invest. 108 (2001) 971-979
57. Takeshita S., Kaji K., and Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J. Bone Miner. Res. 15 (2000) 1477-1488
58. Novack D.V., Yin L., Hagen-Stapleton A., Schreiber R.D., Goeddel D.V., Ross F.P., and Teitelbaum S.L. The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198 (2003) 771-781